Clinical Trial

TrueBinding Announces Results of TB006 Phase 1b/2 Placebo Controlled Proof-of-Concept Trial Showing Improvement on the Primary Cognition and Function Endpoint in Patients with Mild to Severe Alzheimer’s Disease    

Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissueNo dose-limiting toxicities observed in...

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron...

RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea

Glen Rock, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a...

error: Content is protected !!